Patents Assigned to Gilead Sciences, Inc.
  • Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections
    Patent number: 10689399
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 23, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Xiaowu Chen, Jeromy J. Cottell, Manoj C. Desai, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Michael R. Mish, Philip Anthony Morganelli, Hyung-Jung Pyun, James G. Taylor, Teresa Alejandra Trejo Martin
  • Methods of treating feline coronavirus infections
    Patent number: 10682368
    Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 16, 2020
    Assignees: GILEAD SCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michel Joseph Perron, Niels C. Pedersen
  • Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
    Patent number: 10675296
    Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 9, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventor: Nate Larson
  • Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
    Patent number: 10668064
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: June 2, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Mingzhe Ji, Scott E. Lazerwith, Hyung-Jung Pyun
  • Therapeutic compounds
    Patent number: 10654827
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 19, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
    Patent number: 10646486
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 12, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-Jung Pyun
  • Toll like receptor modulator compounds
    Patent number: 10640499
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 5, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Processes for preparing ASK1 inhibitors
    Patent number: 10604490
    Abstract: The present disclosure provides processes for the preparation of a compound of formula: which exhibits apoptosis signal-regulating kinase (“ASK1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 31, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Brandon Heath Brown, Troy Evan Reynolds
  • Cot modulators and methods of use thereof
    Patent number: 10577352
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 3, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Chienhung Chou, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Roland D. Saito, Neil H. Squires, James G. Taylor, William J. Watkins, Nathan E. Wright
  • Antibodies selective for cells presenting EGFR at high density
    Patent number: 10570211
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 25, 2020
    Assignees: GILEAD SCIENCES, INC., NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
    Publication number: 20200048261
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 13, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20200038389
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 6, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant
  • Therapeutic compositions for treatment of human immunodeficiency virus
    Patent number: 10548846
    Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 4, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
  • Quinazoline compounds
    Patent number: 10548898
    Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: February 4, 2020
    Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.
    Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
  • ANTI-HIV COMPOUNDS
    Publication number: 20200030327
    Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
    Type: Application
    Filed: July 29, 2019
    Publication date: January 30, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Elbert Chin, Darryl Kato, John O. Link, Nathan Shapiro, Zheng-Yu Yang
  • Non-selective kinase inhibitors
    Patent number: 10532994
    Abstract: Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: January 14, 2020
    Assignees: PULMOKINE, INC., GILEAD SCIENCES, INC.
    Inventor: Lawrence S Zisman
  • Synthesis of polycyclic-carbamoylpyridone compounds
    Patent number: 10519168
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 31, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Andrew W. Waltman
  • Processes for preparing ACC inhibitors and solid forms thereof
    Patent number: 10519165
    Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 31, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Geier, Norihiro Ikemoto, Sean Liew, Mark E. Scott, Vimal Varghese
  • Solid forms of a toll-like receptor modulator
    Patent number: 10508117
    Abstract: The present invention provides crystalline forms, solvates and hydrates of 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one, and methods of making.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 17, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Patricia Andres, Krista Marie Diaz, Valeriya N. Smolenskaya
  • Apoptosis signal-regulating kinase inhibitor
    Patent number: 10508100
    Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 17, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Gregory Notte